Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

nelfinavir (Rx)Brand and Other Names:Viracept

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

oral powder for suspension

  • 50mg/1g scoopful

tablet

  • 250mg
  • 625mg
more...

HIV Infection

750 mg PO TID, OR

1250 mg PO BID

Other Information

Administration: Take all doses with high-fat meals

Dosage Forms & Strengths

oral powder for suspension

  • 50mg/1g scoopful

tablet

  • 250mg
  • 625mg
more...

HIV Infection

<2 years: Saftey and efficacy not established

2-13 years: 45-55 mg/kg PO BID, OR 25-35 mg/kg PO TID 

Not to exceed adult dose of 2,500 mg/day (BID dosing) or 1,875 mg/day (TID dosing)

Adolescents: As adults: 1,250 mg PO BID, OR 750 mg PO TID

Administration

Mix oral powder with small amount of water, milk, formula or dietary supplement and consume entire dose

Do not mix with acidic food or juice

If not consumed immediately, refrigerate no more than 6 hr

May use crushed 250 mg tablets instead of oral powder

Take all doses with high-fat meals

Other Information

>13 years old: As adult

<2 years old: Safe, but effective dose not established

Next

Interactions

Interaction Checker

nelfinavir and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Diarrhea (14-20%)

            1-10%

            Nausea

            Flatulence

            Abdominal pain

            Anemia

            Allergic reaction

            Hypersensitivity

            Impaired concentration

            Lipodystrophy

            Metabolic acidosis

            Rash

            Leukopenia

            Thrombocytopenia

            Weakness

            <1%

            QTc prolongation

            Torsades de pointes

            Diabetes mellitus, new onset and exacerbation

            Hyperglycemia

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity

            Coadministration with major CYP3A4 substrates and/or inducers

            Drugs that are contraindicated with nelfinavir include alpha1-adrenoreptor agonists (eg, alfuzosin), antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, quinidine), rifampin, voriconazole, ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), cisapride, St. John’s wort, lovastatin, simvastatin, pimozide, sildenafil (when used for PAH), midazolam, and triazolam

            Cautions

            Risk to pregnant/ pediatric pts: EMS (ethyl methanesulfonate) impurity shown to be teratogenic, mutagenic & carcinogenic in animal studies

            Phenylketonurics: oral powder contains phenylalanine

            Risk of immune reconstitution syndrome if used in combination w/ other antiretroviral drugs

            Risk of developing new onset diabetes mellitus; exacerbation of DM & hypoglycemia

            Mod-severe hepatic impairment

            Peds: drug exposure is highly variable

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: B (Antiretroviral Pregnancy Registry established, register pts by calling (800) 258-4263)

            Lactation: HIV+ women are advised not to breastfeed

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Absorption: food increases AUC 2-3x

            Vd: 2-7 L/kg

            Protein Bound: >98%

            Metabolism: hepatic via CYP3A4 & CYP2C19; major metabolite has activity comparable to parent drug

            Half-life, plasma: 3.5-5 hr

            Peak Plasma Time: 2-4 hr

            Enzymes Inhibited: CYP3A4

            Excretion

            Feces: 87%

            Urine: 1-2%

            Mechanism of Action

            HIV-1 protease inhibitor

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.